Market capitalization | $1.22b |
Enterprise Value | $923.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.08 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-100.39m |
Free Cash Flow (TTM) Free Cash Flow | $-68.53m |
Cash position | $291.89m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Imara Inc forecast:
7 Analysts have issued a Imara Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.32 -0.32 |
45%
45%
|
|
EBITDA | -100 -100 |
57%
57%
|
EBIT (Operating Income) EBIT | -100 -100 |
57%
57%
|
Net Profit | -85 -85 |
325%
325%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Samuel Kintz |
Employees | 46 |
Founded | 2019 |
Website | www.enliventherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.